the canadian bar law for the future fund (lfff) has grants available for innovative projects in the field of law.

projects eligible for consideration must be of national interest and/or of benefit to the general public and must be in at least one of the following fields:

• legal research
• legal education
• legislation and law reform
• administration of justice

lfff does not provide funding for capital projects, ongoing operating expenses, budget deficits, general fund drives, annual charitable appeals, scholarships, sabbaticals, conferences and seminars, nor applications relating exclusively to publication costs, equipment purchases or travel costs

the opportunity

here’s what the evidence tells us. demand-led employment strategies — those driven by employer needs — increase the number of people placed in meaningful, long-term jobs and how long they stay in them.

but, in ontario, employers currently play a limited role in designing and delivering employment and training programs.

so let’s figure it out together. how can we more effectively engage ontario employers to improve future outcomes of jobseekers?

what we look for

• does your idea feature a tool, approach, or initiative that will help us identify and test new solutions?
• does your idea have the potential to be developed into a rigorous research project?
• does your idea have the potential for province-wide application?

we give priority to ideas that reflect:

• new opportunities rather than existing initiatives, and
• approaches that build or expand collaborative networks, particularly those involving employers

the fy17 defense appropriations act provides $4 million (m) to the department of defense alcohol and substance abuse disorders research program research program (asadrp). the asadrp is seeking applications to explore integrated approaches to address alcohol and substance use disorder (asud) especially related to traumatic brain injury (tbi) and post-traumatic stress disorder (ptsd) through multidisciplinary, team-based research efforts that translate basic knowledge into enhanced clinical pharmacological treatments protocols. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha) j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

fy17 asadrp program announcement and general application instruction for the following award mechanisms are posted on the grants.gov website.

consortium award – letter of intent due september 13

independent intramural (dod) and extramural investigators at all academic levels (or equivalents) are eligible to submit applications

the asadrp is seeking applications to explore integrated approaches to address alcohol and substance use disorder (asud) especially related to traumatic brain injury (tbi) and post-traumatic stress disorder (ptsd) through multidisciplinary, team-based research efforts that translate basic knowledge into enhanced clinical pharmacological treatments protocols.

·         the program’s approach is to organize multidisciplinary, team-based translational research efforts to:

·         identify promising compounds; 

·         conduct proof-of-principle basic research to determine which compounds are most appropriate for human research trials;

·         conduct human proof-of-concept trials with promising compounds.  this approach should accelerate the translation of contemporary basic science knowledge into enhanced clinical pharmacological treatment protocols for asud, including a regulatory strategy for u.s. food and drug administration (fda) compliance.

·         the cdmrp expects to allocate fy17-19 funding, if appropriated, to fund approximately one asadrp consortium award.  the maximum period of performance is 5 years.  the asadrp consortium will be funded initially with allocations from the fy17 asadrp congressional appropriation ($3.532m). the maximum allowable total costs (direct and indirect) for the entire period of performance are $10.596m (base year plus 2 option years).  two additional options, to be included in the application, may be funded from allocations from the fy18 & fy19 congressional appropriation (up to $3.532m each year) subject to government steering committee (gsc) review, approval of the grants officer, and receipt of future congressional appropriations.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.for more information about the asadrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507
help@ebrap.org

the overarching objective of the ceehrc initiative is to enhance the translation of epigenetics research to health benefits. the goal of this funding opportunity is to support collaborative research teams that have the capability to transform epigenetics research, enhance our understanding of gene-environment interactions, address major health research questions (including health services/policy/economic/ethical, legal or social issues), and foster the application of knowledge gained to the clinic and/or to populations. this funding opportunity thus encourages the long-term translation of research in epigenetics to health benefit through transformational team-based approaches.

specific objectives include but are not limited to:

• improve our understanding of how the physical and social environment interacts with the genome to affect normal and abnormal human development across the life course, including the effects of early life on the brain and mental health (i.e., "social epigenomics");
• enhance our understanding of the origins and mechanisms of disease, especially complex human disease, chronic disease and cancer;
• provide new information regarding the basis of gene-environment interactions, and their implications across populations and generations;
• explore inter- and trans-generational inheritance through biological sex-specific mechanisms; and
• identify and validate new epigenetic biomarkers/ signatures and potential therapeutic or diagnostic targets of relevance for human health and disease.

note: studies of gene-environment interactions across populations, generations and over the life course may include cohort/longitudinal studies examining epigenetic marks.

programs of research that are at an earlier stage of development should consider applying to the ceehrc impact grant funding opportunity, whose objective is to fund both discovery/basic research approaches and more direct heath/disease-related investigations to accelerate the ultimate impact of the research.. substantially similar applications cannot be submitted to both the ceehrc impact and team grant funding opportunities.

through the institute community support (ics) program, the cihr institutes and initiatives are launching the ics travel awards competition for 世界杯2022赛程表淘汰赛 , postdoctoral fellows, new investigators and knowledge users to present their own research at national and international meetings and/or conferences.

this ics travel awards competition will not support travel for research skills development or update, exchange programs or lectureships.

the objectives of this funding opportunity are to:

• enable new and established investigators to undertake innovative clinical trials in the area of type 1 diabetes (t1d);
• support the development and testing of innovative paradigms for clinical studies in adult and pediatric t1d; and
• build capacity for ict research through training and mentoring.

this funding opportunity is a component of the second phase of the canadian epigenetics, environment and health research consortium (ceehrc), which is a pan-canadian initiative led by cihr, with a number of dedicated funding opportunities planned over the next several years.

decades of investment into the genetic basis of disease have led to revolutionary new insights around gene regulation, and the mechanisms through which gene and environment interactions may affect human health. key to these is epigenetics – the study of changes in the regulation of gene activity and expression that are not dependent on gene sequence and that can be environmentally induced. through the first phase of the canadian epigenetics, environment and health research consortium (ceehrc) initiative, and coordinated partnered international efforts, we have learned that many chronic and complex diseases are associated with persistent epigenetic changes. ceehrc recognizes the importance of all levels of research in epigenetics, from individual cells to whole populations. key to all approaches is a focus on collaborative research – namely, integrating different methodologies and disciplines aligned along health needs.

this funding opportunity is intended to support significant progression in epigenetic research where there is the potential to overcome significant challenges or hurdles to translation. these may span the spectrum of basic discovery through to translational research of relevance to the clinic. this program is not intended to support incremental research advances, but ones where the opportunity for high impact breakthroughs is expected. the goals are to promote major advancement in epigenetic research at whatever stage of translation, from the fundamental discovery stage (including studies in model organisms and on basic epigenetic mechanisms), through to applied research (including clinical proof of concept or population-based proposals).  this program provides a new mechanism for ceehrc researchers to accelerate the application of new knowledge in epigenetics that could address key problems with the potential for practical health applications.

research areas

this funding opportunity will support projects relevant, but not limited to, the following research areas:

• complex diseases and chronic conditions, including but not limited to cancer, mental health and  how diet and nutrition can influence chronic disease,
• inflammation and host-microbiome interactions,
• health and wellness considerations for indigenous peoples
• implications for populations with vulnerabilities

alternatively, applications may focus on underlying mechanisms/approaches in epigenetics research that could have broad implications for health and disease. these could include, for example:

• new isolation techniques for characterization of distinct cells within tissues (including single cell assays)
• new methods to reduce the number of cells required for epigenomic assays
• new biomarkers and epigenetic signatures that have the potential to stratify patient populations or disease phenotypes, or predict treatment response
• translation of validated biomarkers into drug-able targets or other therapeutics interventions

• detection and surveillance
• pathway analysis
• prevention and control of disease

• jen weston, research analyst at jen.weston@ontario.ca or (519) 826-3976.

for questions about the rms, please contact:

• sara fisher, research analyst at sara.fisher@ontario.ca or (519) 826-3898 or
• kelly jackson, research analyst at kelly.jackson@ontario.ca or (519)-826-3879

canadian blood services is pleased to announce its 2017 blood efficiency accelerator award program competition. the objective of the program is to improve the efficient and appropriate utilization of blood products, while maintaining the safety of the blood system.

for detailed information about the blood efficiency accelerator award program competition, please refer to www.blood.ca. the deadline to submit completed application packages is august 15 2017.